Literature DB >> 1768566

Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population.

M Tinel1, A Berson, D Pessayre, P Letteron, M P Cattoni, Y Horsmans, D Larrey.   

Abstract

1. A genetic polymorphism in human erythrocyte thiopurine methyltransferase activity (RBC TPMT) resulting in a trimodal phenotypic distribution has been demonstrated both in a North American population and in British children. 2. We studied whether such a polymorphism may be also present in a white French population by testing RBC TPMT activity in 303 randomly selected blood donors. 3. We found a large inter-individual variation in RBC TPMT activity which ranged from 2 to 40 nmol ml-1 packed RBC h-1, with a mean value of 15.4 +/- 7.0 nmol ml-1 packed RBC h-1. The enzyme activity was not significantly influenced by the sex and age of the subjects. 4. In our population sample, we found no subject with undetectable enzyme activity. However, the probit plot of the log RBC TPMT activity showed a highly significant change in slope at a TPMT activity of 7.5 nmol ml-1 packed RBC h-1. Thirty four subjects (11% of our population) had TPMT activities below 7.5 nmol ml-1 packed RBC h-1. 5. These data are consistent with the view that the genetic polymorphism of TPMT activity described in populations from North America and the United Kingdom is also present in a French population, with about 89% of subjects exhibiting a high activity and 11% an intermediate activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1768566      PMCID: PMC1368554     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

Review 1.  Ethnic differences in drug metabolism.

Authors:  W Kalow
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

2.  Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia.

Authors:  L Lennard; C A Rees; J S Lilleyman; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

3.  Severe megaloblastic anaemia associated with abnormal azathioprine metabolism.

Authors:  L Lennard; M F Murphy; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1984-02       Impact factor: 4.335

4.  Thiopurine methyltransferase: mouse kidney and liver assay conditions, biochemical properties and strain variation.

Authors:  D M Otterness; R A Keith; R M Weinshilboum
Journal:  Biochem Pharmacol       Date:  1985-11-01       Impact factor: 5.858

5.  Metabolism of azathioprine to 6-thioguanine nucleotides in patients with pemphigus vulgaris.

Authors:  L Lennard; C I Harrington; M Wood; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

6.  Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic acid derivatives.

Authors:  L C Woodson; M M Ames; C D Selassie; C Hansch; R M Weinshilboum
Journal:  Mol Pharmacol       Date:  1983-11       Impact factor: 4.436

7.  Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations.

Authors:  L Lennard; J A Van Loon; J S Lilleyman; R M Weinshilboum
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

8.  Thiopurine methyltransferase: structure-activity relationships for benzoic acid inhibitors and thiophenol substrates.

Authors:  M M Ames; C D Selassie; L C Woodson; J A Van Loon; C Hansch; R M Weinshilboum
Journal:  J Med Chem       Date:  1986-03       Impact factor: 7.446

9.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.

Authors:  L Lennard; J S Lilleyman; J Van Loon; R M Weinshilboum
Journal:  Lancet       Date:  1990-07-28       Impact factor: 79.321

10.  Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells.

Authors:  L Lennard; S Thomas; C I Harrington; J L Maddocks
Journal:  Br J Dermatol       Date:  1985-12       Impact factor: 9.302

View more
  7 in total

Review 1.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

Review 2.  Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.

Authors:  Tiphaine Adam de Beaumais; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2012-03-16       Impact factor: 2.953

Review 3.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

4.  Identification of factors regulating thiopurine methyltransferase activity in a Norwegian population.

Authors:  B Klemetsdal; B Straume; E Wist; J Aarbakke
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors.

Authors:  E Jacqz-Aigrain; E Bessa; Y Medard; Y Mircheva; E Vilmer
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

6.  NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia.

Authors:  D-C Liang; C-P Yang; H-C Liu; T-H Jaing; S-H Chen; I-J Hung; T-C Yeh; T-H Lin; C-L Lai; C-Y Lai; L-Y Shih
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

7.  Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier.

Authors:  Yitian Zhou; Carolina Dagli Hernandez; Volker M Lauschke
Journal:  Br J Cancer       Date:  2020-09-25       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.